Wilding, John P. H.; Blonde, Lawrence; Leiter, Lawrence A.; Cerdas, Sonia; Tong, Cindy; Yee, Jacqueline; Meininger, Gary
Abstract
Aims: Canagliflozin, a sodium glucose co-transporter 2 inhibitor, has demonstrated glycemic improvements across studies of patients with type 2 diabetes mellitus (T2DM). The impact of canagliflozin on HbA(1c) lowering was assessed by baseline HbA(1c) and known duration of T2DM.; Methods: This post hoc analysis pooled data from patients with T2DM enrolled in four 26-week, placebo-controlled, Phase 3 studies of canagliflozin (N = 2313). Change in HbA(1c), from baseline to Week 26 was assessed in the overall population and in subgroups by baseline HbA(1c) (<8.0%, 8.0%-<9.0%, and >= 9.0%) and known duration of T2DM (<5 years, 5-<10 years, and >= 10years).; Results: Relative to placebo, canagliflozin 100 and 300 mg provided greater HbA(1c), reductions in the overall population. Progressively larger placebo-subtracted reductions in HbAlc with canagliflozin 100 and 300 mg were seen with increasing baseline HbA(1c). HbA(1c) reductions were similar across subgroups based on known duration of T2DM. Both canagliflozin doses were generally well tolerated across subgroups, with a safety and tolerability profile consistent with that seen in Phase 3 studies.; Conclusions: Canagliflozin provided glycemic improvements in patients with T2DM across a range of baseline HbAlc and known duration of T2DM. (C) 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
